Formal
   
   
   
   
 

NeuroResearch Clinics, Inc.
  AMA Category 1
  Continuing Medical Education
Pike Lake Duluth, MN photo by Marty Hinz, MD
 
THE NEURORESEARCH TECHNICAL GUIDE
FOR PHYSICIANS
 
The neurotransmitter approach used in over 900 medical clinics
Contact us or find a caregiver using this approach.
 

Entire Catalog in PDF format
 
Introduction
Medical Education
Treatment
Diseases
Side Effects
LABORATORY
General Discussion
 
 
 
TECHNICAL GUIDE

  The NeuroResearch Clinics Inc. technical guide for physicians. A general overview of the neurotransmitter research work and findings of NeuroResearch since 1997.
 
 
 
NeuroResearch Catalog
alog

Entire Catalog in PDF format
  x01

Front Cover  PDF

  
INTRODUCTION
 

Back to top
Page 1  PDF Partial listing of master serotonin and dopamine neurotransmitter diseases.  x02
Page 2  PDF Sample listing of serotonin and dopamine neurotransmitter diseases and the neurotransmitter associated with the disease.   x03
Page 3  PDF Perspective of this neurotransmitter catalog   x04
Page 4  PDF Index of neurotransmitter subjects 
CONTINUING EDUCATION
 

 
Page 5  PDF Continuing Medical Education, AMA certified category I   x06
Page 6  PDF "68" docs and Flash! Education  
AMINO ACID DISCUSSION
 

 
Page 7  PDF What to do if the 5-HTP, tyrosine, and L-dopa are not working.  x08
Page 8  PDF ON/OFF effect of 5-HTP, tyrosine, and L-dopa. x09
Page 9  PDF 5-HTP, tyrosine, and L-dopa TREATMENT PROTOCOLS   X10
Page 10  PDF 5-HTP, tyrosine, and L-dopa treatment protocols discussion X11
Page 11  PDF The three approaches to 5-HTP, tyrosine, and L-dopatherapy  X12
Page 12  PDF Do not use plain 5-HTP (L-5-HTP or 5HTP)  X13
Page 13  PDF Pitfalls of 5-HTP, tyrosine, and L-dopa therapy  X14
Page 14  PDF Group neurotransmitter treatment optimization and establishing individual 5-HTP, tyrosine, and L-dopa dosing.  X15
Page 15  PDF Use of tyrosine (L-tyrosine) with L-dopa (part 1)  X16
Page 16  PDF Use of tyrosine (L-tyrosine) with L-dopa (part 2)  X17
Page 17  PDF Expectations of treatment
TREATING INDIVIDUAL DISEASES  X18
 

Back to top
Page 18  PDF Depression (part 1)  X19
Page 19  PDF Depression (part 2)  x20
Page 20  PDF Insomnia and hyper-somnolence  x21
Page 21  PDF Parkinsonism (part 1)  x22
Page 22  PDF Parkinsonism (part 2) and ADHD (part 1)  x23
Page 23  PDF ADHD (part 2) and treating pediatric patients  x24
Page 24  PDF ADHD drugs discussion  x25
Page 25  PDF Migraine headaches, chronic pain, and anti-aging considerations  x26
Page 26  PDF Hormones, adrenal burnout  x27
Page 27  PDF OCD, anorexia, bulimia  x28
Page 28  PDF Obesity (part 1)  x29
Page 29  PDF Obesity (part 2)
SIDE EFFECT OVERVIEW AND MANAGEMENT

Page 30 Side effect profile and management of prescription neurotransmitter drug side effects
Page 31 GI upset on starting 5-HTP, tyrosine, and L-dopa
Page 32 GI upset carbohydrate intolerance
Page 33 GI upset from cysteine and paradoxical reactions (part 1)
Page 34 Paradoxical reactions (part 2)
Page 35 Heart burn, dizziness, and hyper-somnolence
URINARY NEUROTRANSMITTER LABORATORY CONSIDERATIONS

Back to top
Page 36 DBS Labs Introduction
Page 37 The value of baseline neurotransmitter testing prior to starting amino acids
Page 38 Where urinary neurotransmitter molecules are synthesized (the source).
Page 39 The three phases of urinary neurotransmitter response to amino acids
Page 40 The Phase 3 Response of dopamine and serotonin
Page 41 Urinary neurotransmitter testing overview (part 1)
Page 42 Urinary neurotransmitter testing overview (part 2)
Page 43 Urinary neurotransmitter testing and resolution of disease symptoms (the bull's eye)
Page 44 Urinary neurotransmitter testing sample collection time considerations
Page 45 Urinary neurotransmitter testing, doing it right
Page 46 Urinary neurotransmitter levels in patients not under treatment with amino acids
Page 47 Urinary neurotransmitters pearls of treatment and testing stats (part 1)
Page 48 Urinary neurotransmitter stats (part 2)
Page 49 The balance between serotonin and dopamine
Page 50 Neurotransmitter lab results discussion (part 1)
Page 51 Neurotransmitter lab results discussion (part 2)
Page 52 Neurotransmitter lab results discussion (part 3)
Page 53 The tip of the iceberg (part 1)
Page 54 The tip of the iceberg (part 2)
OTHER MASTER NEUROTRANSMITTER CONSIDERATIONS

Back to top
Page 55 How prescription drugs deplete neurotransmitters
Page 56 If you have to use prescription drugs prevent depletion of neurotransmitters
Page 57 N-acetyl-tyrosine considerations
Page 58 N-acetyl-cysteine considerations
Page 59 Beta phenylethylamine (PEA) considerations
Page 60 GABA considerations in clinical practice
Page 61 Prioritizing medical care
Page 62 Cortisol and neurotransmitters
Page 63 Hormones and neurotransmitters
Page 64 Melatonin and the minor neurotransmitters
Page 65 Obesity amino acids and other treatment modalities
Page 66 Bibliography (part 1)
Page 67 Bibliography (part 2)
Page 68 Bibliography (part 3)
Page 69 Bibliography (part 4)
Page 70 Patient brochure
Page 71 Back cover

coverBack to top
Front Cover
Back to previous link

neurotransmitter catalog cover

1Back to top
Page 1
Back to previous link

neurotransmitter disease algorythm

2Back to top
Page 2
Back to previous link

neurotransmitters relating to disease

3Back to top
Page 3
Back to previous link

neurotransmitter perspective

4Back to top
Page 4
Back to previous link

neurotransmitter index

5Back to top
Page 5
Back to previous link

neurotransmiter education

6Back to top
Page 6
Back to previous link

neurotransmitter medical education needs

7Back to top
Page 7
Back to previous link

neurotransmitter failures

8Back to top
Page 8
Back to previous link

neurotransmitter stops working

9Back to top
Page 9
Back to previous link

neurotransmitter optimal protocol

10Back to top
Page 10
Back to previous link

neurotransmiter basics

11Back to top
Page 11
Back to previous link

neurotransmitter three approaches

12Back to top
Page 12
Back to previous page

neurotransmitter dopamine depletion

13Back to top
Page 13
Back to previous link

neurotransmitter problems of treatment

14Back to top
Page 14
Back to previous link

neurotransmitter how much to dose

15Back to top
Page 15
Back to previous link

neurotransmitter tyrosine base

16Back to top
Page 16
Back to previous link

neurotransmitter stabilization

17Back to top
Page 17
Back to previous page

neurotransmitter treatment expectations

18Back to top
Page 18
Back to previous page

neurotransmitters and depression

19Back to top
Page 19
Back to previous page

neurotransmitters with depression

20Back to top
Page 20
Back to previous link

neurotransmitters cause insomnia

21Back to top
Page 21
Back to previous link

neurotransmitters and parkinsonism

22Back to top
Page 22
Back to previous link

neurotransmitter parkinsonism considerations

23Back to top
Page 23
Back to previous link

neurotransmitters in kids ADHD

24Back to top
Page 24
Back to previous link

neurotransmitter ADHD drug depletion

25Back to top
Page 25
Back to previous link

neurotransmitters and pain

26Back to top
Page 26
Back to previous link

neurotransmitters hormones and adrenal burnout

27Back to top
Page 27
Back to previous page

neurotransmitters OCD bulimia anorexia

28Back to top
Page 28
Back to previous link

neurotransmitter and obesity

29Back to top
Page 29
Back to previous link

neurotransmitter obesity overview
Back to top
If you need a medical speaker for AMA Category I CME call NeuroResearch Clinics, Inc.
NeuroResearch Clinics, Inc. only deals with and provides information to licensed health care professionals.
 
NeuroResearch Clinics, Inc 
1150 88th Ave W 
Duluth, MN 55808 
Ph. 877-626-2220 
E-Mail: Info@NeuroAssist.com 
 

DISCLAIMER: NeuroResearch is a research company that provides speakers to programs for AMA category I continuing medical education (CME) for physicians, continuing education for psychologists approved by the American Psychological Association, and licenses intellectual property for use. The NeuroResearch formulas and theory of medicine is designed for the use of combining amino acid precursors of the serotonin and catecholamine systems. The formulas are intended to be used as nutritional supplements and not as a drug to treat, mitigate, treat, cure, or prevent disease.   This web site is intended to be educational purposes only. Constantly we receive e-mails from people who are not licensed health care providers. We wish we could answer them, but the new telemedicine laws that were recently legislated (and put in place) prohibit us from providing advice directly to people with no medical license or providing medical care over the Internet.